focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 118.00
Bid: 116.00
Ask: 120.00
Change: 0.00 (0.00%)
Spread: 4.00 (3.448%)
Open: 118.00
High: 118.00
Low: 118.00
Prev. Close: 118.00
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal of non-core product line

4 Apr 2024 07:00

RNS Number : 2155J
Eco Animal Health Group PLC
04 April 2024
 

4 April 2024

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Disposal of non-core product line

Disposal streamlines ECO Animal Health's product and pipeline focus

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy ("ACME"), its long-term manufacturing partner, for a total consideration of €1.3m.

Continuing to streamline the business

ECO is focused on treatment and prevention of disease in pigs and poultry. ECOmectin® Horsepaste is a branded treatment for equine parasites based upon the ivermectin active ingredient and has for some time been non-core to the business. 

The Transaction

ACME has acquired all the marketing authorisations held by ECO for the ECOmectin® Horsepaste, together with the intellectual property, manufacturing and distribution arrangements and existing inventory ("the Transaction"). The marketing authorisations are principally within the UK and EU. In addition, ACME has been granted a trademark licence to market and sell the horse paste under the ECOmectin® brand. 

The total consideration for the Transaction is €1.3m; €500,000 was paid on signature of the sale and purchase agreement with an undertaking to pay two further payments of €400,000 each on the date which is 18 months after completion and 36 months after completion. These two elements of deferred consideration are unconditional and supported with a bank guarantee which will be put in place within 45 days.

The revenue derived from this business in the year ending 31 March 2024 was £814,000 (2023 £988,000).

Reinvesting to support our pipeline

The Board believes that the Transaction further streamlines ECOs focus on its core species of pigs and poultry and in particular on developing its highly innovative pipeline of vaccines and preventatives. It is intended that the funds received from the Transaction will be invested in research and development to support new product development.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "The disposal of ECOmectin® Horsepaste is in line with our stated intention of focusing on treatments and preventatives in pigs and poultry and this enables us to increase investment in our R&D pipeline. The brand and the broader business is a good fit for ACME Drugs S.r.l and we are pleased that the business will be taken forward by a committed owner.

"We continue to look for value accretive opportunities both within our portfolio and outside and for opportunities to reinvest in our R&D pipeline to support future growth."

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISSSIFIDELSEDL
Date   Source Headline
23rd Apr 20153:04 pmBUSTransaction in Own Shares
15th Apr 201512:12 pmBUSIssue of Equity
14th Apr 201511:47 amBUSIssue of Equity
13th Apr 20157:00 amBUSTrading Statement
17th Mar 201510:50 amBUSTransaction in Own Shares
11th Mar 20153:43 pmBUSDirector/PDMR Shareholding - Replacement
2nd Mar 20159:37 amBUSIssue of Equity
26th Feb 20159:19 amBUSIssue of Equity
23rd Feb 20155:00 pmBUSHolding(s) in Company
18th Feb 20159:20 amBUSDirector/PDMR Shareholding
12th Feb 20153:24 pmBUSCirc re.Share buy-back programme
26th Jan 20152:03 pmBUSIssue of Equity
22nd Jan 201510:56 amBUSDirector/PDMR Shareholding
21st Jan 20159:22 amBUSHolding(s) in Company
13th Jan 20154:54 pmBUSIssue of Equity
22nd Dec 20141:26 pmBUSDirectorate Change
3rd Dec 20147:00 amBUSHalf-yearly Report
31st Oct 20149:18 amBUSHolding(s) in Company
18th Sep 201411:07 amBUSResult of AGM
29th Aug 201410:35 amBUSDirector/PDMR Shareholding
30th Jul 201410:24 amBUSCirc re.Posting of Annual Report and Notice of Meeting
28th Jul 20147:00 amBUSFinal Results
10th Jun 20147:00 amBUSChange of Nomad
13th Mar 20149:50 amBUSIssue of Equity
25th Feb 20149:06 amBUSRegulatory Approval
25th Feb 20147:00 amBUSRegulatory Application
3rd Feb 20147:00 amBUSRegulatory Approval
28th Jan 201412:45 pmBUSHolding(s) in Company
27th Jan 20147:00 amBUSRegulatory Approval
10th Dec 20137:00 amBUSHalf-yearly Report
2nd Dec 20137:00 amBUSRegulatory Approval
28th Nov 201310:23 amBUSIssue of Equity
28th Nov 20139:22 amBUSHolding(s) in Company
28th Oct 20137:00 amBUSRegulatory Approval
25th Oct 20133:03 pmBUSHolding(s) in Company
24th Oct 20133:04 pmBUSHolding(s) in Company
24th Oct 20132:57 pmBUSIssue of Equity
22nd Oct 20133:03 pmBUSResult of EGM
15th Oct 20131:29 pmBUSCirc re.Issue of Options
3rd Oct 20139:33 amBUSIssue of Equity
25th Sep 201312:38 pmBUSHolding(s) in Company
19th Sep 201311:28 amBUSCirc re. Scrip dividend scheme
6th Sep 20134:16 pmBUSIssue of Equity
28th Aug 201310:09 amBUSCirc re. Issue of options
25th Jul 201311:45 amBUSCirc re.Annual Report and Accounts 2013
12th Jul 20137:00 amBUSFinal Results
26th Apr 20133:47 pmBUSIssue of Equity
5th Mar 20139:36 amBUSIssue of Equity
15th Jan 201312:15 pmBUSIssue of Equity
12th Dec 20127:00 amBUSHalf-yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.